Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | KDM4A | O75164 | 1/20 | 0.32 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.32 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25654223 | 0.98 | BLM (0.32) | KDM4CCHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL25728553 | 0.93 | KDM4C (0.32) | KDM4CCHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL22906427 | 0.84 | CHRNB2 (0.33) | KDM4CCHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL26368451 | 0.83 | BLM (0.32) | KDM4CCHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL23696586 | 0.83 | KDM4C (0.32) | KDM4CCHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL21107030 | 0.82 | PIK3CD (0.30) | — | |
| SCHEMBL23806837 | 0.82 | BLM (0.30) | BLM | |
| SCHEMBL22849684 | 0.81 | KDM4C (0.34) | KDM4CCHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL21106571 | 0.81 | BLM (0.32) | KDM4CCHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL23807314 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219945-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219945-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | KDM4C 293/4885CHRNB2 4503/4885CHRNB4 4564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.